CLIMB BIO INC
CLYMNASDAQπ #2699 by market capUS Equity
$9.20β
Last available close Β· quote unavailableTrack CLYM
Get earnings, price moves & breaking news on Telegram
24hβ
7dβΌ 11.2%
14dβΌ 10.7%
30dβΌ 9.6%
ytdβ² 129.9%
1yβ² 439.3%
π¦Market Cap
$540M
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
0.0%
Thin
π΅FCF Margin
0.0%
Thin
βοΈP/S Ratio
0.0x
Cheap
Otter Score
60
Fair
Trading Snapshot
- Day Range
- β
- 52-Week Range
- $1.64 β $18.33
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 58.7M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -11.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.74
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4.1%
CLIMB BIO INC
CLYMFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$68MβΌ β17.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$55Mβ² +250.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
67.4Mβ² +4.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$35MβΌ β$52M YoY
About CLIMB BIO INC
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Fair
60/100
Analyst data unavailable.
Latest News & Updates
News unavailable.